Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: An Asian-Pacific perspective

Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy

“…Since, Chan et al (2007) concluded in their review that metformin is an effective as other oral anti-diabetic agents in controlling blood glucose, and the initiation of oral anti-diabetic pharmacotherapy with metformin has been shown to significantly reduce the risk of a range of macrovascular endpoints in a prospective randomized study (the UKPDS) and in large retrospective analyses. Traditionally, metformin is viewed as the initiating pharmacotherapy of choice in overweight/obese diabetic patients; however, in light of new evidence, this view is now changing.…”

“…Traditionally, metformin is viewed as the initiating pharmacotherapy of choice in overweight/obese diabetic patients; however, in light of new evidence, this view is now changing. Both the IDF global guidelines and regional recommendations for the Asian-Pacific region have broadened their recommendations to include metformin within the options for initiating oral anti-diabetic therapy for all patients irrespective of BMI (Chan et al, 2007). In people who are overweight (body mass index over 25.0 kg/m 2 ) and whose blood glucose is inadequately controlled using lifestyle interventions alone, metformin should normally be used as the first-line glucose-lowering therapy, these recommendation based on evidence from meta-analysis of randomized controlled trials, or from at least one randomized controlled trial (McIntosh et al, 2001).…”

The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study

“…In UK Prospective Diabetes Study, it has been demonstrated that intensive glucose control with metformin appeared to decrease the risk of diabetes‐related end‐points including macrovascular complications in overweight diabetic patients, and was associated with less weight gain and fewer hypoglycaemic events than that with insulin and sulphonylureas (4). Because of its unique mechanism of action and cardiovascular advantage and proven safety profiles, metformin has been recommended by the International Diabetes Federation and the other professional groups as the initial option for pharmacotherapy in patients with type 2 diabetes (5–7).…”

Safety, tolerability, and efficacy of metformin extended‐release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia

“…Implementing evidence‐based measures to improve the prevention and management of type 2 diabetes mellitus (T2DM) is a paramount public health priority in Asia 1 . A shift towards energy‐rich diets and sedentary “obesogenic” modern lifestyles, brought about by increasing affluence and rapid urbanization, and population aging are contributing to the escalating prevalence of T2DM in the Asia–Pacific region 1–4 . World Health Organization (WHO) 5 figures project that the number of people with diabetes worldwide, 95% or more of whom have T2DM, will double by 2030 and that Asia–Pacific countries, which are home to more than half of the world’s population, will bear the greatest burden.…”